Are there clinically significant differences between dopamine agonists

Adv Neurol. 2003:91:259-66.
No abstract available

Publication types

  • Review

MeSH terms

  • Antiparkinson Agents / administration & dosage
  • Antiparkinson Agents / adverse effects
  • Antiparkinson Agents / pharmacokinetics*
  • Clinical Trials as Topic
  • Disorders of Excessive Somnolence / chemically induced
  • Disorders of Excessive Somnolence / physiopathology
  • Dopamine Agonists / administration & dosage
  • Dopamine Agonists / adverse effects
  • Dopamine Agonists / pharmacokinetics*
  • Dyskinesia, Drug-Induced / physiopathology
  • Dyskinesia, Drug-Induced / prevention & control
  • Humans
  • Levodopa / adverse effects
  • Parkinson Disease / drug therapy*
  • Parkinson Disease / metabolism
  • Parkinson Disease / physiopathology
  • Receptors, Dopamine / drug effects
  • Receptors, Dopamine / metabolism

Substances

  • Antiparkinson Agents
  • Dopamine Agonists
  • Receptors, Dopamine
  • Levodopa